2009
Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001.
Rugo H, Carey L, Mayer E, Marcom P, Liu M, Ma C, Storniolo A, Forero A, Esteva F, Wolff A, Hobday T, Ferraro M, Davidson N, Winer E, Moore D, Scott J, Park J. Assays of circulating tumor cells and outcome in the triple-negative breast cancer trial TBCRC001. Cancer Research 2009, 69: 6048. DOI: 10.1158/0008-5472.sabcs-6048.Peer-Reviewed Original ResearchBasal-like breast cancerArm 1Study treatmentCTC levelsTumor cellsPhase II studyPhase II trialTime pointsBreast cancer trialsMarkers of activityRank correlation coefficientCc bloodMetastatic BrCaShorter TSTPrimary endpointII studyII trialObjective responseFirst infusionCancer trialsEfficacy dataArm 2Breast cancerCTC measurementCTC enumeration
2008
Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer
Buzdar AU, Coombes RC, Goss PE, Winer EP. Summary of aromatase inhibitor clinical trials in postmenopausal women with early breast cancer. Cancer 2008, 112: 700-709. PMID: 18072256, DOI: 10.1002/cncr.23193.Peer-Reviewed Original ResearchConceptsAromatase inhibitorsEndocrine therapyAdjuvant therapyPostmenopausal womenClinical trialsBreast cancerEstrogen receptor-positive breast cancerEfficacy of AIsReceptor-positive breast cancerInitial adjuvant therapyEarly breast cancerEnd-organ effectsGold standard treatmentYears of treatmentAI therapyThrombolic eventsNight sweatsSkeletal eventsVaginal bleedingEndometrial cancerHot flashesBone resorptionEfficacy dataDisease outcomeOptimal duration